Epidermal growth factor receptor intron 1 polymorphism and microsatellite instability in sporadic colorectal cancer

Epidermal growth factor receptor (EGFR) expression is commonly upregulated in sporadic colorectal cancer (CRC) and its high expression is associated with poor prognosis in patients with CRC. CA-SSR1 is a dinucleotide CA repeat of the EGFR gene that can modulate EGFR transcription and is a potential target of the mismatch repair machinery in tumours with microsatellite instability (MSI). In the present study, 160 sporadic colon cancer samples were analysed for EGFR CA-SSR1 polymorphism and MSI status. Additionally, EGFR mRNA and protein expression levels in the tumour centre and in the invasive tumour front, compared with those in adjacent normal tissue samples, were evaluated in 80 tumour samples. An inverse association was identified between EGFR mRNA levels and the sum of repeats in both alleles of the CA-SSR1 polymorphism in normal tissues. Changes in CA-SSR1 were detected in the tumour centre as well as in the invasive tumour front and metastases in all MSI high (MSI-H) tumours. Analysis of EGFR expression at the mRNA and protein levels according to MSI status revealed lower EGFR mRNA and protein expression in MSI-H tumours than microsatellite-stable (MSS) tumours. Furthermore, higher EGFR levels in the invasive tumour front compared with in the tumour centre in MSS tumours were identified, suggesting a role of EGFR in tumour progression and higher invasive potential of MSS than MSI-H tumours.

[1]  N. Kushlinskii,et al.  EGFR Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis , 2020, Journal of oncology.

[2]  L. Corchete,et al.  Prognostic implications of EGFR protein expression in sporadic colorectal tumors: Correlation with copy number status, mRNA levels and miRNA regulation , 2020, Scientific Reports.

[3]  A. Bardelli,et al.  Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. , 2019, Cancer treatment reviews.

[4]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[5]  Hung-Ming Wang,et al.  Epidermal growth factor receptor intron-1 CA repeat polymorphism on protein expression and clinical outcome in Taiwanese oral squamous cell carcinoma , 2017, Scientific Reports.

[6]  M. Kloor,et al.  The Immune Biology of Microsatellite-Unstable Cancer. , 2016, Trends in cancer.

[7]  Tetsuo Nemoto,et al.  A three-tier classification system based on the depth of submucosal invasion and budding/sprouting can improve the treatment strategy for T1 colorectal cancer: a retrospective multicenter study , 2015, Modern Pathology.

[8]  P. Gibbs,et al.  Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  J. Izbicki,et al.  EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer , 2014, Targeted Oncology.

[10]  C. Futter,et al.  EGF receptor trafficking: consequences for signaling and cancer , 2014, Trends in cell biology.

[11]  R. Medeiros,et al.  EGFR signaling pathway and related-miRNAs in age-related diseases: the example of miR-221 and miR-222 , 2012, Front. Gene..

[12]  H. Sasaki,et al.  Polymorphisms in intron 1 of the EGFR gene in non-small cell lung cancer patients , 2012, Experimental and therapeutic medicine.

[13]  R. Palmqvist,et al.  Increased epidermal growth factor receptor expression at the invasive margin is a negative prognostic factor in colorectal cancer , 2011, International journal of cancer.

[14]  Won‐Suk Lee,et al.  Mutations in K-ras and Epidermal Growth Factor Receptor Expression in Korean Patients With Stages III and IV Colorectal Cancer , 2011, International journal of surgical pathology.

[15]  Matej Horvat,et al.  Microsatellite instability in colorectal cancer , 2011, Radiology and oncology.

[16]  Seung-Yong Jeong,et al.  Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer , 2011, Cancer Chemotherapy and Pharmacology.

[17]  Y. Bang,et al.  Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6 , 2010, Cancer science.

[18]  D. Sargent,et al.  Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status , 2009, British Journal of Cancer.

[19]  Sanjay Goel,et al.  An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression. , 2009, Cancer research.

[20]  J. Lindebjerg,et al.  The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  J. Bramis,et al.  P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up. , 2009, Anticancer research.

[22]  H. Lenz,et al.  Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab , 2008, Clinical Cancer Research.

[23]  Horst Buerger,et al.  Biological importance of a polymorphic CA sequence within intron 1 of the epidermal growth factor receptor gene (EGFR) in high grade central osteosarcomas , 2008, Genes, chromosomes & cancer.

[24]  T. Lesuffleur,et al.  Frequent mutations of the CA simple sequence repeat in intron 1 of EGFR in mismatch repair-deficient colorectal cancers. , 2008, World journal of gastroenterology.

[25]  J. Park,et al.  Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study , 2007, BMC Cancer.

[26]  K. Tanimoto,et al.  EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung. , 2007, Oncology reports.

[27]  J. Siegfried,et al.  Association of the EGFR intron 1 CA repeat length with lung cancer risk , 2007, Molecular carcinogenesis.

[28]  M. Heslin,et al.  Pancreatic Cancer Epidermal Growth Factor Receptor (EGFR) Intron 1 Polymorphism Influences Postoperative Patient Survival and in vitro Erlotinib Response , 2007, Annals of Surgical Oncology.

[29]  B. Brandt,et al.  Mechanisms of egfr Gene Transcription Modulation: Relationship to Cancer Risk and Therapy Response , 2006, Clinical Cancer Research.

[30]  Dong Hyun Choi,et al.  Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type , 2006, Journal of Clinical Pathology.

[31]  W. Gerald,et al.  Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study , 2005, Modern Pathology.

[32]  N. Magné,et al.  Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  M. Kloor,et al.  Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases , 2005, British Journal of Cancer.

[34]  K. Pavelić,et al.  NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer , 2005, Gut.

[35]  Manuel Hidalgo,et al.  An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors , 2004, Cancer Research.

[36]  Hidetaka Mochizuki,et al.  Risk factors for an adverse outcome in early invasive colorectal carcinoma. , 2004, Gastroenterology.

[37]  M. Perucho.  Tumors with microsatellite instability: many mutations, targets and paradoxes , 2003, Oncogene.

[38]  H. McLeod,et al.  Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. , 2002, European journal of cancer.

[39]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[40]  R. Simon,et al.  Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. , 2000, Cancer research.

[41]  K. Zänker,et al.  Modulation of Epidermal Growth Factor Receptor Gene Transcription by a Polymorphic Dinucleotide Repeat in Intron 1* , 1999, The Journal of Biological Chemistry.

[42]  M. Morimatsu,et al.  An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer , 1989, Cancer.

[43]  S. Cohen.  ISOLATION AND BIOLOGICAL EFFECTS OF AN EPIDERMAL GROWTH-STIMULATING PROTEIN. , 1964, National Cancer Institute monograph.

[44]  J. Sambrook,et al.  Isolation of High-Molecular-Weight DNA from Mammalian Blood Using Proteinase K and Phenol. , 2017, Cold Spring Harbor protocols.

[45]  G. Freeman,et al.  The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. , 2015, Cancer discovery.

[46]  S. Varadarajulu,et al.  Epidermal growth factor receptor (EGFR) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma. , 2010, American journal of surgery.

[47]  C. Jung,et al.  Clinicopathologic Significances of EGFR Expression at Invasive Front of Colorectal Cancer , 2010 .

[48]  F. Penault-Llorca,et al.  Impact of EGFR expression on colorectal cancer patient prognosis and survival. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  K. Pavelić,et al.  Human tumour bank in Croatia: a possible model for a small bank as part of the future European tumour bank network. , 1994, European journal of cancer.

[50]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.